Company
Brisbane, QLD
Every investor coverage indicates participated in a round Peplin, Inc. raised.
The transaction that ended Peplin, Inc.'s run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| LEO Pharma A/S | Acquisition | Sep 2009 | US$287.5m | GBS Ventures (25 May 2010), GBS Ventures (12 Nov 2009) |
Companies Peplin, Inc. acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Eugene Bauer | President and Chief Medical Officer | GBS Ventures (12 Nov 2009), GBS Ventures (18 Aug 2008) |
| Dr Peter Welburn | Chief Scientific Officer | GBS Ventures (12 Nov 2009), GBS Ventures (8 Jan 2009) |
| Michael Aldridge | CEO (former) | GBS Ventures (25 May 2010), GBS Ventures (18 Aug 2008) |
| Tom Wiggans | Chief Executive Officer | GBS Ventures (23 Jul 2009), GBS Ventures (8 Jan 2009), GBS Ventures (16 Dec 2008), GBS Ventures (18 Aug 2008) |
Stories naming Peplin, Inc.. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
LEO Pharma's acquisition of Peplin is done, a deal agreed in September 2009 for about US$287.5 million. Peplin continues as a LEO subsidiary led by chief executive George Mahaffey, keeping Australian operations.
Also GBS Ventures
Peplin has begun a second Phase 3 trial of its skin-lesion gel, seeking to confirm earlier clearance results at non-head sites, with a regulatory filing planned for mid-2010.
Peplin reports its PEP005 gel met the primary endpoint in a Phase IIb actinic keratosis trial, clearing lesions safely across doses and moving toward Phase III development.
ASX-listed biotech Peplin has finished enrolling 250 patients in the first Phase III trial of its PEP005 Gel treatment for actinic keratosis, with results expected in H1 2009.
Peplin hires Tom Wiggans as CEO and Eugene Bauer as President/CMO while Michael Aldridge steps down; the dermatology company also announces a US$24m capital raising and a merger agreement with Neosil.